

Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).

Title: Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).

Publication year: 2025

Journal: British journal of cancer

Authors: Department of Pediatric and AYA Oncology, Oscar Lambret Center, Lille, France. as-defachelles@o-lambret.fr.

Society: European pediatric soft tissue sarcoma study group (EpSSG)

Origin country: International

Target countries: Europe

DOI: 10.1038/s41416-025-03130-1

PMID: 40913059

Source: <https://pubmed.ncbi.nlm.nih.gov/40913059/>

Br J Cancer Br J Cancer 334 brjcancer 0370635 British Journal of Cancer 0007-0920 1532-1827 Nature Publishing Group PMC12644882 PMC12644882.1 12644882 12644882 40913059 10.1038/s41416-025-03130-1 3130 1 Review Article Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (E p SSG) <http://orcid.org/0000-0002-4277-9871> Defachelles A. S. as-defachelles@o-lambret.fr 1 Breunis W. B. 2 Casanova M. 3 Minard-Collin V. 4 Hjadun R. 5 Wasti A. 6 Dávila Fajardo R. 7 8 Terwisscha van Scheltinga S. 8 Heenen D. 9 Heinz A. T. 10 11 Sparber-Sauer M. 10 11 Merks J. H. M. 8 12 <http://orcid.org/0000-0003-3479-7997> Chisholm J. C. 13 <http://orcid.org/0000-0002-6438-9778> Gatz S. A. 14 15 1 <https://ror.org/03xfq7a50> grid.452351.4 0000 0001 0131 6312 Department of Pediatric and AYA Oncology, Oscar Lambret Center, Lille, France 2 <https://ror.org/035vb3h42> grid.412341.1 0000 0001 0726 4330 Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland 3 <https://ror.org/05dwj7825> grid.417893.0 0000 0001 0807 2568 Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy 4 <https://ror.org/0321g0743> grid.14925.3b 0000 0001 2284 9388 Department of Paediatric Oncology, Gustave Roussy, Paris, France 5 <https://ror.org/052g8jq94> grid.7080.f 0000 0001 2296 0625 Pediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain 6 <https://ror.org/043jzw605> grid.18886.3f 0000 0001 1499 0189 The Institute of Cancer Research, London, UK 7 <https://ror.org/0575yy874> grid.7692.a 0000 0000 9012 6352 Radiation Oncology department, University Medical Center Utrecht, Utrecht, the Netherlands 8 <https://ror.org/02aj7yc53> grid.487647.e Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 9 KickCancer Foundation, Brussels, Belgium 10 <https://ror.org/03esvmb28> grid.488549.c Department of Hematology and Oncology, University Children's Hospital Tübingen, Tübingen, Germany 11 <https://ror.org/01xet8208> grid.459687.1 0000 0004 0493 3975 Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany 12 <https://ror.org/04pp8hn57> grid.5477.1 0000000120346234 Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands 13 <https://ror.org/034vb5t35> grid.424926.f 0000 0004 0417 0461 Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK 14 <https://ror.org/03angcq70> grid.6572.6 0000 0004 1936 7486 Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK 15 <https://ror.org/056ajev02> grid.498025.2 0000 0004 0376 6175 Department of Paediatric Oncology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK 5 9 2025 14 12 2025 133 11 501170 1591 1598 1 4 2025 11 6 2025 10 7 2025 05 09 2026 26 11 2025 26 11 2025 © The Author(s), under exclusive licence to Springer Nature Limited 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement

with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

2025 At least one-third of patients with localized rhabdomyosarcoma (RMS) and 60–70% of patients with metastatic RMS experience progressive disease or relapse. Following relapse, outcomes generally remain poor with limited treatment options and a high risk of subsequent recurrence. Optimal treatment requires a multidisciplinary approach incorporating chemotherapy with local control. Given the complexity of managing relapsed RMS and the challenges in developing effective treatment strategies, we aim to present clear and practical recommendations on the management of these patients across Europe. These recommendations were developed collaboratively by a group of pediatric and adolescent sarcoma experts from the European paediatric Soft Tissue Sarcoma Study Group. A careful review of the literature was performed to ensure that wherever possible recommendations are supported by the results of clinical trials or substantive retrospective reports. Such recommendations provide a standardized approach to managing relapsed cases, improving patient outcomes and offering a framework for clinicians to make informed decisions.